Program
zanzalintinib
Also written as “Zanzalintinib” and “XL092”.
Its studies are mostly in Carcinoma, Renal Cell · Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Adenoma, Islet Cell, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exelixis | 1312 open or running | phase 3since Jun 16, 2022 | Feb 15, 2019 | Dec 15, 2026phase 3 · NCT05678673 |
| Merck | 33 open or running | phase 3since Nov 7, 2025 | Jun 25, 2025 | Nov 27, 2030phase 3 · NCT07489495 |
| Hoffmann-La Roche | 10 open or running | phase 2since Nov 7, 2017 | Nov 7, 2017 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 7, 2017.
- Jun 16, 2022Phase 3 study in Colorectal NeoplasmsExelixis · NCT05425940 · 901 enrolled · United States, Australia, Belgium and more
- Dec 23, 2022Phase 3 study in Non-Clear Cell Renal Cell CarcinomaExelixis · NCT05678673 · 317 enrolled · United States, Argentina, Australia and more
- Oct 9, 2023Phase 3 study in Squamous Cell Carcinoma of Head and NeckExelixis · NCT06082167 · 600 enrolled · United States, Argentina, Australia and more
- Dec 19, 2023Phase 1 study in Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsExelixis · NCT06191796 · 25 enrolled · United States
- Apr 17, 2025Phase 3 study in Adenoma, Islet CellExelixis · NCT06943755 · 440 planned · United States, Australia, Austria and more
- Apr 30, 2025Phase 1 study in Hepatic ImpairmentExelixis · NCT06962332 · 20 planned · United States
- Jun 25, 2025Merck’s first study: phase 2 study in Carcinoma, Renal CellNew to MerckMerck · NCT07049926 · 140 planned · United States, Chile, France and more
- Nov 7, 2025Phase 3 study in Carcinoma, Renal CellMerck · NCT07227402 · 904 planned · United States, Argentina, Australia and more
- Feb 19, 2026Phase 2 study in MeningiomaExelixis · NCT07428616 · 100 planned · United States
- Mar 20, 2026Phase 3 study in Carcinoma, Renal CellMerck · NCT07489495 · 758 planned · United States, Argentina, Australia and more
- May 27, 2026Phase 3 study in NeoplasmsExelixis · NCT07620574 · 5,000 planned · United States
- Aug 3, 2026Phase 3 study in Colorectal NeoplasmsExelixis · NCT07750158 · 600 planned · United States
- Aug 12, 2026Phase 1 study in NeoplasmsExelixis · NCT07773454 · 18 planned
- Sep 22, 2026Phase 2 study in Squamous Non-Small Cell Lung Cancer (NSCLC)Exelixis · NCT07845786 · 60 planned · United States
Ahead
- Dec 15, 2026Primary completion: phase 3 study in Non-Clear Cell Renal Cell CarcinomaExelixis · NCT05678673
- Jan 31, 2027Primary completion: phase 1 study in Carcinoma, Renal CellExelixis · NCT05176483
- Feb 29, 2028Primary completion: phase 2 study in MeningiomaExelixis · NCT07428616
- Jun 15, 2028Primary completion: phase 2 study in Squamous Non-Small Cell Lung Cancer (NSCLC)Exelixis · NCT07845786
TargetBeta
“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, ”NCIt, by rule
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07845786Squamous Non-Small Cell Lung Cancer (NSCLC) · United States | 2 | Recruiting | Exelixis | Jun 15, 2028 | 60 |
| NCT07773454Neoplasms | 1 | Not yet recruiting | Exelixis | Jul 31, 2028 | 18 |
| NCT07750158Colorectal Neoplasms · United States | 3 | Recruiting | Exelixis | Apr 5, 2030 | 600 |
| NCT07620574Neoplasms · United States | 3 | By invitation | Exelixis | May 31, 2030 | 5,000 |
| NCT07489495Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Nov 27, 2030 | 758 |
| NCT07428616Meningioma · United States | 2 | Recruiting | Exelixis | Feb 29, 2028 | 100 |
| NCT07227402Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Feb 27, 2032 | 904 |
| NCT07049926Carcinoma, Renal Cell · United States, Chile, France and more | 2 | Recruiting | Merck | Oct 26, 2031 | 140 |
| NCT06962332Hepatic Impairment · United States | 1 | Recruiting | Exelixis | Dec 2025 | 20 |
| NCT06943755Adenoma, Islet Cell · United States, Australia, Austria and more | 3 | Recruiting | Exelixis | Jun 30, 2029 | 440 |
| NCT06191796Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors · United States | 1 | Terminated | Exelixis | May 12, 2025 | 25 |
| NCT06082167Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Aug 2028 | 600 |
| NCT05678673Non-Clear Cell Renal Cell Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Dec 15, 2026 | 317 |
| NCT05425940Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Exelixis | Jun 16, 2026 | 901 |
| NCT05176483Carcinoma, Renal Cell · United States, Australia, Austria and more | 1 | Recruiting | Exelixis | Jan 31, 2027 | 1,394 |
| NCT03845166Neoplasms · United States, Australia, Belgium and more | 1 | Active, not recruiting | Exelixis | Aug 31, 2026 | 325 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
How it is read
Names in the registry
- “Zanzalintinib”, 12 entries
- “XL092”, 4 entries
- “zanzalintinib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 6 studies
- Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Adenoma, Islet Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.